Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Following US President-elect Donald Trump's announcement that Robert F Kennedy (RFK) Jr will be appointed as head of the ...

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

Novoxel Inc. announces the U.S. FDA clearance of the Tixel i (pronounced "Tixel Eye") for sale in the USA. The newest member of ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Lorati Company Limited has introduced a groundbreaking advancement in the treatment of age-related macular degeneration (AMD), including both dry and wet forms, with its nano-grade eye drops. Mr.

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

While some companies like Amgen, Pfizer, Bristol Myers Squibb Company (BMY), and others appeared attractive ... was recently approved by the FDA for COPD treatment. However, this approval occurred ...